Burning Rock Biotech (BNR)
(Delayed Data from NSDQ)
$0.85 USD
0.00 (-0.01%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $0.88 +0.03 (3.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Burning Rock Biotech Limited Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 76 | 82 | 80 | 66 | NA |
Cost Of Goods | 25 | 27 | 23 | 18 | NA |
Gross Profit | 51 | 55 | 57 | 48 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 145 | 197 | 182 | 111 | 0 |
Income After Depreciation & Amortization | -94 | -142 | -125 | -63 | 0 |
Non-Operating Income | 3 | 2 | 0 | 1 | NA |
Interest Expense | NA | 0 | 0 | 0 | NA |
Pretax Income | -92 | -141 | -125 | -62 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | NA | 0 | 0 | 0 | NA |
Investment Gains/Losses | NA | 0 | 0 | 0 | NA |
Other Income/Charges | NA | 0 | 0 | 0 | NA |
Income From Cont. Operations | -92 | -141 | -125 | -62 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -92 | -141 | -125 | -62 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -94 | -124 | -118 | -58 | 0 |
Depreciation & Amortization (Cash Flow) | NA | 18 | 8 | 5 | NA |
Income After Depreciation & Amortization | -94 | -142 | -125 | -63 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 102.40 | 103.91 | 104.18 | 51.31 | NA |
Diluted EPS Before Non-Recurring Items | -0.90 | -1.36 | -1.20 | -1.05 | NA |
Diluted Net EPS (GAAP) | -0.90 | -1.36 | -1.20 | -1.05 | NA |
Fiscal Year end for Burning Rock Biotech Limited Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 17.05 | 17.49 | 20.17 | 20.75 |
Cost Of Goods | NA | 6.14 | 5.71 | 6.32 | 6.37 |
Gross Profit | NA | 11.15 | 11.78 | 13.85 | 14.38 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 34.76 | 36.28 | 32.57 | 41.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -23.61 | -24.50 | -18.72 | -27.45 |
Non-Operating Income | NA | 0.74 | 0.59 | 0.68 | 0.53 |
Interest Expense | NA | NA | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -22.86 | -23.92 | -18.04 | -26.91 |
Income Taxes | NA | 0.15 | 0.06 | 0.06 | 0.06 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -22.85 | -23.98 | -18.10 | -26.98 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -22.85 | -23.98 | -18.10 | -26.98 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 102.40 | 102.33 | 85.15 | 102.39 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.23 | -0.18 | -0.26 |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.23 | -0.18 | -0.26 |